ELV Elevance Health Inc

$ELV — Two bounces off the purple EMA. Is a breakout next? 👀 $ELV has held the purple EMA twice and is now consolidating below resistance, forming a sideways box with signs of tightening price action. Meanwhile, Healthcare continues to show strong relative strength against $SPY. The structure looks promising, but I'd rather see tighter compression before the next move. Can buyers push $ELV through resistance toward new highs? Anyone else watching this setup? 🎯

$ELV Benefit expense ratio came in at 90.6% in Q3, down from 91.3% a year ago and below the 91.1% consensus, mostly Medicare Advantage and individual ACA doing better. Adjusted EPS was 6.99 dollars vs 4.71 expected, though 1.85 dollars of that was a net nonoperating benefit. Still raised the full-year adjusted guide to at least 29 dollars, from at least 27.

$ELV Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $6.99 up 15.92% YoY • Reported revenue of $50.44B up 0.70% YoY • Elevance Health raised FY 2026 diluted EPS guidance to at least $22.00, adjusted diluted EPS guidance to at least $29.00, and operating cash flow guidance to at least $6.5B.

$ELV Elevance reports Q3 Wednesday before the open. Zacks consensus is 4.66 dollars EPS on 48.60 billion dollars revenue, down 22.7% and 3% YoY. Zacks models the Q3 benefit expense ratio at 91.4%, well above the 90.2% full-year guide, plus or minus 50bp, that the company reaffirmed on Sept 10, alongside adjusted EPS of at least 27 dollars. Membership is modeled smaller too, 44.26 million vs 45.37 million a year ago, with Medicare Advantage at 1.86 million vs 2.25 million.